Suchergebnisse - "Khera, Nandita"

PubPharm (200)

1

Trends in Volumes and Survival After Hematopoietic Cell Transplantation in Racial/Ethnic Minorities

enthalten in: Blood advances | 2024

von Khera, N. | Ailawadhi, S. | Brazauskas, R. | +40

2

TP53 variant allele frequency and therapy-related setting independently predict survival in myelodysplastic syndromes with del(5q)

enthalten in: British journal of haematology | 2024

von Tefferi, A. | Fleti, F. | Chan, O. | +18

3

Family-Focused Facilitated Fitness : Feasibility and Acceptability of a Couple-Based Physical Activity Intervention for Hematopoietic Cell Transplant Recipients and Their Caregiving Partners

enthalten in: Transplantation and cellular therapy | 2024

von Langer, S. | Joseph, R. | Mistretta, E. | +4

4

Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies

enthalten in: Advances in therapy | 2024

von Khera, N. | Edwards, M. | Song, Y. | +7

5

Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Levis, M. | Hamadani, M. | Logan, B. | +137

6

Lung Injury Prediction Model in Bone Marrow Transplantation : A Multicenter Cohort Study

enthalten in: American journal of respiratory and critical care medicine | 2024

von Herasevich, S. | Schulte, P. | Hogan, W. | +7

CommentIn: Am J Respir Crit Care Med. 2024 Mar 1;209(5):473-476. - PMID 38285548

7

Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies

enthalten in: Advances in therapy | 2024

von Khera, N. | Edwards, M. | Song, Y. | +7

8

Financial hardship for patients with cancer and caregivers at end of life in the USA : narrative review

enthalten in: BMJ supportive & palliative care | 2024

von Salazar, M. | Khera, N. | Chino, F. | +1

9

Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia : Comparative analysis of response, toxicity, and survival

enthalten in: American journal of hematology | 2024

von Karrar, O. | Abdelmagid, M. | Rana, M. | +23

10

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia : Genotype signatures for response and survival among 301 consecutive patients

enthalten in: American journal of hematology | 2024

von Gangat, N. | Karrar, O. | Iftikhar, M. | +23

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[20]